OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
Further Strengthens Global Intellectual Property Portfolio for Tedopi® in Non-Small Cell Lung Cancer until 2035 NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announced today that it has received …